Global Hemophilia Treatment Market Is Expected To Reach Around USD 16,310 Million By 2025

Zion Market Research  has published a new report titled “Hemophilia Treatment Market by Type (Hemophilia A, Hemophilia B, and Hemophilia C), by Product (Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrates, Antifibrinolytic Agents, and Desmopressin), and by Therapy (Replacement and Gene): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025”. According to the report, the global hemophilia treatment market was approximately USD 10,692 million in 2018 and is expected to generate around USD 16,310 million by 2025, at a CAGR of around 6.24% between 2019 and 2025.

Hemophilia is commonly a genetic rare bleeding disorder that restricts blood clotting in a proper way, as it deficiencies adequate blood-clotting proteins (clotting factor). This condition tends to occur mainly in males. People with hemophilia do not bleed any faster than normal but can bleed for an extended time after an injury than anyone would have if their blood clotted normally. Hemophilia treatment involves the replacement of the specific needed clotting factor via a tube inserted in a vein. The prescribed treatment for hemophilia depends on the condition’s severity. The two foremost treatment approaches are preventive treatment, in which medicine is used to prevent bleeding and muscle damage, and on-demand treatment, where medicine is used for prolonged bleeding.

Browse the full “Hemophilia Treatment Market by Type (Hemophilia A, Hemophilia B, and Hemophilia C), by Product (Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrates, Antifibrinolytic Agents, and Desmopressin), and by Therapy (Replacement and Gene): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018–2025” Report at https://www.zionmarketresearch.com/report/hemophilia-treatment-market

The global hemophilia treatment market is growing due to increasing bleeding disorder prevalence and their rising severity, advancing medical knowledge, and the rising number of scientific research activities. The National Hemophilia Foundation states that more than 400,000 people are affected by the disorder and 75% of people still lack adequate treatment options for the same. Additionally, the increasing use of prophylactic treatment for hemophilia, the invention of novel coagulating factors, technological advancements, flourishing biotechnology sector, increasing awareness among people, escalating research and development focused on identifying curative agents are other key factors driving the global hemophilia treatment market. However, the high treatment costs, stringent government regulations, and lack of available medicines may restrain the hemophilia treatment market growth.

The hemophilia treatment market is fragmented on the basis of type, product, and therapy. Based on type, the market includes Hemophilia A, B, and C. Hemophilia A held the largest market share in 2018, due to its increasing prevalence and rising awareness among the people regarding its treatment.

By product, the market is classified into desmopressin, plasma derived coagulation factor concentrates, recombinant coagulation factor concentrates, and antifibrinolytic agents. The recombinant coagulation factor concentrates segment dominated the global hemophilia treatment market in 2018 and is expected to grow rapidly in the future. This can be attributed to the rising recombinant coagulation factor concentrates demand as it helps to treat hemophilia and overcome the limited availability of plasma derived concentrates.

The therapy segment of the market comprises gene and replacement therapy. Gene therapy is expected to show the highest CAGR in the global market in the future.

North America dominated the global hemophilia treatment market in 2018, due to the increasing prevalence of bleeding disorder and their rising severity, rising preference toward prophylaxis treatment, the rising ability of effective gene therapy, and the regional presence of key market players. The Asia Pacific hemophilia treatment market will show the highest CAGR over the forecast time period, owing to the increasing prevalence of hemophilia disease and growing use of recombinant products.

Some key players operating in the global hemophilia treatment market are Pfizer, Baxalta, Baxter International, CSL Ltd., Octapharma, Grifols, Novo Nordisk, Kedrion, Bayer, Biogen Idec, and Hospira.

This report segments the global hemophilia treatment market into:

Global Hemophilia Treatment Market: By Type

• Hemophilia A
• Hemophilia B
• Hemophilia C

Global Hemophilia Treatment Market: By Product

• Recombinant Coagulation Factor Concentrates
• Plasma Derived Coagulation Factor Concentrates
• Antifibrinolytic Agents
• Desmopressin

Global Pediatrics Healthcare Market: By Therapy

• Replacement Therapy
• Gene Therapy

Global Hemophilia Treatment Market: By Region

• North America
  • The U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• The Middle East and Africa

About Us:
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com